LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)

BACKGROUND: Antibiotics elicit intestinal dysbiosis with short and long-term deleterious effects. A colon-targeted adsorbent, DAV132, prevents dysbiosis in healthy humans and may protect antibiotic-treated patients. METHODS: Hospitalized patients receiving oral/iv fluoroquinolones (FQ) for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducher, Annie, Vehreschild, Maria J G T, Louie, Thomas J, Cornely, Oliver A, Féger, Céline, Dane, Aaron, Varastet, Marina, de Gunzburg, Jean, Andremont, Antoine, Mentré, France
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776914/
http://dx.doi.org/10.1093/ofid/ofaa515.1902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776914/
http://dx.doi.org/10.1093/ofid/ofaa515.1902

Ejemplares similares